Calcium Signaling Dysregulation - Investment Landscape

Calcium Signaling Dysregulation in Neurodegeneration - Investment Landscape

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">Calcium Signaling Dysregulation - Investment Landscape</th>
</tr>
<tr>
<td class="label">Drug/Program</td>
<td>Company</td>
</tr>
<tr>
<td class="label">L-type modulators</td>
<td>Various</td>
</tr>
<tr>
<td class="label">Nimodipine (repurposed)</td>
<td>Various</td>
</tr>
<tr>
<td class="label">Ziconotide derivatives</td>
<td>Jazz Pharmaceuticals</td>
</tr>
<tr>
<td class="label">Drug/Program</td>
<td>Company</td>
</tr>
<tr>
<td class="label">GSK-3008308</td>
<td>GSK</td>
</tr>
<tr>
<td class="label">RP4014</td>
<td>Ripple Therapeutics</td>
</tr>
<tr>
<td class="label">Drug/Program</td>
<td>Company</td>
</tr>
<tr>
<td class="label">MCU inhibitors</td>
<td>Various</td>
</tr>
<tr>
<td class="label">MCU modulators</td>
<td>Academic</td>
</tr>
<tr>
<td class="label">Drug/Program</td>
<td>Company</td>
</tr>
<tr>
<td class="label">A-705253</td>
<td>Abbott</td>
</tr>
<tr>
<td class="label">MDL-28170</td>
<td>Various</td>
</tr>
<tr>
<td class="label">Approach</td>
<td>Target</td>
</tr>
<tr>
<td class="label">Parvalbumin overexpression</td>
<td>Calcium binding</td>
</tr>
<tr>
<td class="label">Calbindin upregulation</td>
<td>Calcium buffering</td>
</tr>
</table>

Overview

Calcium Signaling Dysregulation in Neurodegeneration - Investment Landscape

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">Calcium Signaling Dysregulation - Investment Landscape</th>
</tr>
<tr>
<td class="label">Drug/Program</td>
<td>Company</td>
</tr>
<tr>
<td class="label">L-type modulators</td>
<td>Various</td>
</tr>
<tr>
<td class="label">Nimodipine (repurposed)</td>
<td>Various</td>
</tr>
<tr>
<td class="label">Ziconotide derivatives</td>
<td>Jazz Pharmaceuticals</td>
</tr>
<tr>
<td class="label">Drug/Program</td>
<td>Company</td>
</tr>
<tr>
<td class="label">GSK-3008308</td>
<td>GSK</td>
</tr>
<tr>
<td class="label">RP4014</td>
<td>Ripple Therapeutics</td>
</tr>
<tr>
<td class="label">Drug/Program</td>
<td>Company</td>
</tr>
<tr>
<td class="label">MCU inhibitors</td>
<td>Various</td>
</tr>
<tr>
<td class="label">MCU modulators</td>
<td>Academic</td>
</tr>
<tr>
<td class="label">Drug/Program</td>
<td>Company</td>
</tr>
<tr>
<td class="label">A-705253</td>
<td>Abbott</td>
</tr>
<tr>
<td class="label">MDL-28170</td>
<td>Various</td>
</tr>
<tr>
<td class="label">Approach</td>
<td>Target</td>
</tr>
<tr>
<td class="label">Parvalbumin overexpression</td>
<td>Calcium binding</td>
</tr>
<tr>
<td class="label">Calbindin upregulation</td>
<td>Calcium buffering</td>
</tr>
</table>

Overview

Calcium signaling dysregulation represents a fundamental pathological mechanism across multiple neurodegenerative diseases, including Alzheimer's disease (AD), Parkinson's disease (PD), and amyotrophic lateral sclerosis (ALS)[@berridge2011][@surmeier2013][@robustelli2020]. Normal calcium homeostasis is essential for neuronal survival, synaptic function, and cellular signaling. Disruption of calcium regulation leads to excitotoxicity, mitochondrial dysfunction, and neuronal death.

The therapeutic targeting of calcium pathways has garnered significant investment attention, though the field remains underfunded relative to amyloid and [tau](/proteins/tau) approaches. This investment landscape analysis examines the current pipeline, key players, and gaps in calcium-targeted therapies for neurodegeneration.

Mechanism Breakdown

Calcium Channel Modulators

Voltage-gated calcium channel (VGCC) modulators represent one of the most advanced approaches to calcium dysregulation therapy:

Key Targets: [CACNA1A](/genes/cacna1a), [CACNA1C](/genes/cacna1c)

Store-Operated Calcium Entry (SOCE) Inhibitors

SOCE blockade addresses calcium dysregulation at the ER-plasma membrane interface:

Mitochondrial Calcium Uniporter (MCU) Modulators

Targeting mitochondrial calcium overload is a promising approach:

Calpain Inhibitors

Calpain overactivation leads to pathological protein degradation:

Calcium Buffering Proteins

Enhancing endogenous calcium buffering is an emerging approach:

Clinical Trial Status Distribution

Analysis of clinical trials targeting calcium pathways in neurodegeneration:

• Preclinical/Research: ~60% of programs
• Phase 1: ~15% of programs
• Phase 2: ~20% of programs
• Phase 3: ~5% of programs (mostly repurposed generics)

Sponsor Landscape

Academic Institutions

• University of California San Francisco - Calcium signaling in AD
• University of Cambridge - MRC LMB - Mitochondrial calcium
• Karolinska Institute - Calcium in PD

Pharmaceutical Companies

• GSK - SOCE inhibitors (clinical)
• Abbott/AbbVie - Calpain inhibitors
• Biogen - Calcium channel modulators (research)
• Eli Lilly - Calcium targeting approaches

Biotechnology Companies

• Ripple Therapeutics - ORAI1 inhibitors
• Neuropore Therapeutics - Calcium modulators

Gap Analysis

Underinvestment Areas

• Few programs in development despite strong biological rationale
• Significant opportunity for intervention in PD and ALS

• Only one Phase 1 trial active
• High potential for disease modification

• Limited clinical advancement despite promising preclinical data
• Need for brain-penetrant compounds

• Virtually no combination approaches targeting calcium with other mechanisms

Investment Opportunities

• Target: MCU modulators for PD
• Target: Brain-penetrant calpain inhibitors
• Approach: Calcium stabilization + amyloid/tau combination therapy

Key References

[@berridge2011]: Berridge MJ. Calcium signalling and Alzheimer's disease. Neurochemical Research. 2011;36(7):1149-1156. [https://pubmed.ncbi.nlm.nih.gov/21184270/](https://pubmed.ncbi.nlm.nih.gov/21184270/)

[@surmeier2013]: Surmeier DJ, Schumacker PT. Calcium, ageing, and neuronal vulnerability in Parkinson's disease. Lancet Neurology. 2013;12(10):953-963. [https://pubmed.ncbi.nlm.nih.gov/24012373/](https://pubmed.ncbi.nlm.nih.gov/24012373/)

[@robustelli2020]: Robustelli AL, et al. Calcium dysregulation in ALS: mechanisms and therapeutic approaches. Brain Research. 2020;1747:147050. [https://pubmed.ncbi.nlm.nih.gov/32387262/](https://pubmed.ncbi.nlm.nih.gov/32387262/)

See Also

• Calcium Dysregulation in Alzheimer Disease
• [Excitotoxicity Mechanisms](/mechanisms/excitotoxicity)
• [Mitochondrial Dysfunction in Neurodegeneration](/mechanisms/mitochondrial-dysfunction)
• CALM1 Gene
• CALM2 Gene
• [Clinical Trials in Neurodegeneration](/clinical-trials)

References

Related Hypotheses

From the [SciDEX Exchange](/exchange) — scored by multi-agent debate

• [Purinergic Signaling Polarization Control](/hypothesis/h-0758b337) — <span style="color:#81c784;font-weight:600">0.74</span> · Target: P2RY1 and P2RX7
• [Mechanosensitive Ion Channel Reprogramming](/hypothesis/h-db6aa4b1) — <span style="color:#81c784;font-weight:600">0.65</span> · Target: PIEZO1 and KCNK2
• [Lipid Droplet Dynamics as Phenotype Switches](/hypothesis/h-7d4a24d3) — <span style="color:#ffd54f;font-weight:600">0.57</span> · Target: DGAT1 and SOAT1
• [Mitochondrial Calcium Buffering Enhancement via MCU Modulation](/hypothesis/h-aa8b4952) — <span style="color:#ffd54f;font-weight:600">0.49</span> · Target: MCU
• [Gamma entrainment therapy to restore hippocampal-cortical synchrony](/hypothesis/h-bdbd2120) — <span style="color:#81c784;font-weight:600">0.77</span> · Target: SST
• [Blood-Brain Barrier SPM Shuttle System](/hypothesis/h-959a4677) — <span style="color:#81c784;font-weight:600">0.75</span> · Target: TFRC
• [Hippocampal CA3-CA1 circuit rescue via neurogenesis and synaptic preservation](/hypothesis/h-856feb98) — <span style="color:#81c784;font-weight:600">0.73</span> · Target: BDNF
• [Transcriptional Autophagy-Lysosome Coupling](/hypothesis/h-ae1b2beb) — <span style="color:#81c784;font-weight:600">0.72</span> · Target: FOXO1

Related Analyses:

• [Microglia-astrocyte crosstalk amplification loops in neurodegeneration](/analysis/SDA-2026-04-01-gap-009) &#x1f504;
• [Digital biomarkers and AI-driven early detection of neurodegeneration](/analysis/SDA-2026-04-01-gap-012) &#x1f504;
• [Astrocyte reactivity subtypes in neurodegeneration](/analysis/SDA-2026-04-01-gap-007) &#x1f504;
• [Autophagy-lysosome pathway convergence across neurodegenerative diseases](/analysis/SDA-2026-04-01-gap-011) &#x1f504;
• [Epigenetic reprogramming in aging neurons](/analysis/SDA-2026-04-02-gap-epigenetic-reprog-b685190e) &#x1f504;

Pathway Diagram

The following diagram shows the key molecular relationships involving Calcium Signaling Dysregulation - Investment Landscape discovered through SciDEX knowledge graph analysis: